Related Experiment Video
Updated: May 10, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
Consensus Statement on Drug-Coated Balloons in Coronary Artery Disease from the Cardiovascular Intervention
Pannipa Suwannasom1, Korakoth Towashiraporn2, Worawut Roongsangmanoon3
1Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Insights
Drug-coated balloons (DCBs) offer an alternative to drug-eluting stents (DESs) in percutaneous coronary intervention (PCI). This consensus provides guidance on DCB use, lesion preparation, and antiplatelet therapy for optimal patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- Drug-coated balloons (DCBs) deliver antiproliferative drugs without permanent scaffolds in percutaneous coronary intervention (PCI).
- Indications for DCBs have expanded from in-stent restenosis (ISR) to small vessel and bifurcation lesions.
- Variability exists in patient/lesion selection, preparation, and dual antiplatelet therapy (DAPT) duration post-DCB angioplasty.
Purpose of the Study:
- To establish a consensus statement on the use of DCBs in coronary interventions.
- To provide structured recommendations for optimal DCB therapy in clinical practice.
Main Methods:
- Systematic review of randomized controlled trials, meta-analyses, and real-world studies by the CIAT expert panel.
- Appraisal of procedural strategies, imaging guidance, physiologic assessment, and antiplatelet protocols.
- Recommendations developed and voted on, with consensus defined by 80% agreement.
Main Results:
- DCBs show comparable outcomes to drug-eluting stents (DESs) in selected lesions, allowing shorter DAPT durations.
- Optimal DCB outcomes depend on meticulous lesion preparation, appropriate balloon sizing, and controlled dissection.
- Intravascular imaging, physiologic assessment, and hybrid strategies enhance procedural precision for complex cases.
Conclusions:
- DCB angioplasty serves as a viable alternative or complement to DESs in various clinical and anatomical settings.
- The CIAT consensus offers structured guidance for implementing DCB therapy.
- Adherence to recommendations can optimize patient outcomes and support contemporary DCB practice.
Abstract:
Background: Drug-coated balloons (DCBs) have transformed percutaneous coronary intervention (PCI) by delivering antiproliferative drugs without leaving a permanent scaffold. DCB is initially indicated for in-stent restenosis (ISR) and now has expanded indication for treating small vessel disease and bifurcation lesions. However, there is a heterogeneity in the patient and lesion selection, lesion preparation techniques, and the optimal duration of dual antiplatelet therapy after DCB angioplasty. The Cardiovascular Intervention Association of Thailand (CIAT) developed a consensus statement on DCB use in coronary interventions. Methods: The CIAT expert panel systematically reviewed randomized controlled trials, meta-analyses, and real-world studies evaluating DCB therapy. Procedural strategies, imaging guidance, physiologic assessment, and antiplatelet therapy protocols were appraised. The recommendations were developed and put to an online vote. Consensus was defined when the recommendation reached 80% of votes in support of "agree" or "neutral". Results: Clinical evidence demonstrates that DCBs achieve comparable outcomes to drug-eluting stents (DESs) in selected lesions while enabling shorter durations of dual antiplatelet therapy (DAPT), particularly beneficial for high-bleeding-risk patients. Optimal outcomes require meticulous lesion preparation, appropriate balloon sizing, and controlled vessel dissection. Intravascular imaging and physiologic assessment further refine procedural precision, while hybrid strategies combining DCBs and DESs address complex lesions and multivessel disease. The final document presents 15 consensus statements addressing indications, procedural techniques, imaging and physiologic guidance, and antiplatelet therapy recommendations. Conclusions: DCB angioplasty can be an alternative or complement to therapeutic options to DESs across multiple clinical and anatomical scenarios. The CIAT consensus provided structured recommendations to support DCB therapy in contemporary practice.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

